Lisata Therapeutics adjourns preferred conversion vote; 2026 equity plans approved
At its November 9, 2026 annual meeting, Lisata Therapeutics stockholders approved the 2026 Equity Incentive Plan, the 2026 Employee Stock Purchase Plan, and a reverse stock split authorization with a ratio between 1-for-5 and 1-for-15. The vote on the Series C preferred stock conversion proposal, which would exceed 20% of outstanding common stock and result in a change of control, was not held and the meeting was adjourned. The conversion vote will resume at a reconvened meeting on November 30, 2026.
Key points
- 2026 Equity Incentive Plan approved with an initial reserve of 44,764,472 shares; 2,924,154 votes for and 1,552,345 against.
- 2026 Employee Stock Purchase Plan approved with an initial reserve of 3,730,372 shares.
- Reverse stock split proposal approved with a ratio to be set by the Board between 1-for-5 and 1-for-15; 7,524,706 votes for.
- Series C preferred conversion proposal not voted; reconvened meeting set for November 30, 2026 at 11:00 a.m. Eastern.
The filing
Written by AI on Nov 9, 2026, 5:21 PM ET, from this filing only.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.